Crinetics Pharmaceuticals Europe

Company snapshot

Crinetics Pharmaceuticals is a global [pharmaceutical company](en.wikipedia.org/wiki/Pharmaceutical_ind) known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in [San Diego, California](en.wikipedia.org/wiki/San_Diego). It went public on [NASDAQ](en.wikipedia.org/wiki

• 2 approved product(s) across US/EU regulatory metadata.
• 12 active pipeline program(s) linked via ClinicalTrials.gov.
• 26 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Crinetics Pharmaceuticals Europe. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Crinetics Pharmaceuticals Europe.

1. Jun 8, 2026 Clinical update

   Paltusotine — Phase 3

2. Jun 8, 2026 Clinical update

   Paltusotine — Phase 3

3. Jun 5, 2026 Clinical update

   Randomized: 40 mg Paltusotine — Phase 2

4. Jun 5, 2026 Clinical update

   CRN09682 — Phase 2

5. Jun 5, 2026 Clinical update

   CRN04894 Oral Solution — Phase 1

View all clinical trial activity →

• What is Crinetics Pharmaceuticals Europe?

  Crinetics Pharmaceuticals Europe is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker CRNX. Primary therapeutic focus areas include Congenital Adrenal Hyperplasia, Carcinoid Syndrome, Cushing Syndrome, SST2-positive Neuroendocrine Neoplasms, Ac

• Is Crinetics Pharmaceuticals Europe publicly traded?

  Yes. Crinetics Pharmaceuticals Europe is listed with ticker CRNX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Crinetics Pharmaceuticals Europe develop or market?

  We link 4 drug profile(s) where Crinetics Pharmaceuticals Europe is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/crinetics-pharmaceuticals#company-drugs.

• What are the latest developments for Crinetics Pharmaceuticals Europe?

  In the last 12 months our linked public records show 12 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Crinetics Pharmaceuticals Europe focus on?

  Crinetics Pharmaceuticals Europe focuses on Congenital Adrenal Hyperplasia, Carcinoid Syndrome, Cushing Syndrome based on our analysis of their pipeline programs and drug development activities.